H.R. 8205, the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, passed the House on July 22, 2026.
H.R. 8205 — Accelerating Access to Critical Therapies for ALS Reauthori…
What it does
This bill extends and improves a 2022 law designed to speed up development of treatments for ALS (amyotrophic lateral sclerosis), a fatal neurodegenerative disease. It renews the program through 2031, adds requirements for the FDA to review clinical trial progress and request interim data from drug manufacturers, clarifies what counts as a qualifying clinical trial, and mandates the FDA publish a detailed report on its ALS and rare neurodegenerative disease initiatives within one year.
Quorum's transparency scan found no buried provisions in Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
What happens next
H.R. 8205 passed the House. It now moves to the other chamber.
Who is behind it
Filed by Mike Quigley. Cosponsored by Adam Smith, Adelita Grijalva, Alma Adams and Analilia Mejia.